Acelrx Pharmaceuticals (ACRX)

Acelrx (ACRX) Stock Price & Analysis


ACRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.57 - $7.61
Previous Close$0.72
Average Volume (3M)229.24K
Market Cap
Enterprise Value$2.80M
Total Cash (Recent Filing)$15.93M
Total Debt (Recent Filing)$12.47M
Price to Earnings (P/E)0.1
Mar 30, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.23
Shares Outstanding8,198,110
10 Day Avg. Volume173,640
30 Day Avg. Volume229,239
Standard Deviation0.21
Financial Highlights & Ratios
Price to Book (P/B)0.69
Price to Sales (P/S)8.37
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.84
Enterprise Value/Gross Profit-2.99
Enterprise Value/Ebitda0.06
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Acelrx Pharmaceuticals’s price range in the past 12 months?
Acelrx Pharmaceuticals lowest stock price was $0.57 and its highest was $7.61 in the past 12 months.
    What is Acelrx Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Acelrx Pharmaceuticals’s upcoming earnings report date?
    Acelrx Pharmaceuticals’s upcoming earnings report date is Mar 30, 2023 which is in 6 days.
      How were Acelrx Pharmaceuticals’s earnings last quarter?
      Acelrx Pharmaceuticals released its earnings results on Nov 14, 2022. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$1.2 by $0.26.
        Is Acelrx Pharmaceuticals overvalued?
        According to Wall Street analysts Acelrx Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Acelrx Pharmaceuticals pay dividends?
          Acelrx Pharmaceuticals does not currently pay dividends.
          What is Acelrx Pharmaceuticals’s EPS estimate?
          Acelrx Pharmaceuticals’s EPS estimate is -$10.2.
            How many shares outstanding does Acelrx Pharmaceuticals have?
            Acelrx Pharmaceuticals has 8,198,110 shares outstanding.
              What happened to Acelrx Pharmaceuticals’s price movement after its last earnings report?
              Acelrx Pharmaceuticals reported an EPS of -$0.94 in its last earnings report, beating expectations of -$1.2. Following the earnings report the stock price went up 3.704%.
                Which hedge fund is a major shareholder of Acelrx Pharmaceuticals?
                Currently, no hedge funds are holding shares in ACRX


                Acelrx Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Acelrx Pharmaceuticals

                AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Emmaus Life Sciences
                CB Scientific
                Acer Therapeutics
                Jaguar Animal Health

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis